Aptose Presents Data At ASH 2024 Supporting Tuspetinib Triple Therapy With Venetoclax And Azacitidine In Newly Diagnosed AML, Highlighting Broad Efficacy In FLT3 Wildtype And Prior-VEN Failure Populations, Favorable Safety, And Potential To Establish...
Aptose Presents Data At ASH 2024 Supporting Tuspetinib Triple Therapy With Venetoclax And Azacitidine In Newly Diagnosed AML, Highlighting Broad Efficacy In FLT3 Wildtype And Prior-VEN Failure Populations, Favorable Safety, And Potential To Establish...
Aptose在2024年ASH大会上展示了支持Tuspetinib与Venetoclax和Azacitidine联合治疗新诊断的急性髓性白血病（AML）的数据，强调了在FLT3野生型和先前VEN失败人群中的广泛疗效，良好的安全性，以及建立潜力...
Aptose Presents Data At ASH 2024 Supporting Tuspetinib Triple Therapy With Venetoclax And Azacitidine In Newly Diagnosed AML, Highlighting Broad Efficacy In FLT3 Wildtype And Prior-VEN Failure Populations, Favorable Safety, And Potential To Establish Mutation-Agnostic Standard Of Care For Chemotherapy-Ineligible Patients
Aptose 在 2024 年 ASH 年会展示数据，支持与 Venetoclax 和 Azacitidine 结合的 Tuspetinib 三联疗法用于新诊断的急性髓系白血病，突出了在 FLT3 常规型和先前耐 Venetoclax 失败人群中的广泛疗效，良好的安全性，并有潜力为不适合化疗的患者建立无突变标准治疗。
资讯热榜
更新时间